Risk factor analysis for piperacillin-tazobactam-resistant Enterobacter spp. bacteremia at a tertiary hospital

Diagn Microbiol Infect Dis. 2021 Feb 10;100(2):115342. doi: 10.1016/j.diagmicrobio.2021.115342. Online ahead of print.


This study aimed to analyze the risk factors for piperacillin-tazobactam (TZP1)-resistant Enterobacter spp. bacteremia. The medical records of 111 patients with Enterobacter spp. bacteremia divided into a TZP-susceptible group (minimum inhibitory concentrations [MICs2] ≤16 μg/mL) and TZP-resistant group (MICs >16 μg/mL) were retrospectively reviewed. The male-to-female ratio, age, underlying disease, and infection site did not differ between the 2 groups. Multivariate analysis revealed that the independent predictor associated with TZP-resistant Enterobacter spp. bacteremia was the previous usage of third-generation cephalosporins (P = 0.036). In conclusion, TZP administration in cases of suspected Enterobacter spp. bacteremia previously treated with third-generation cephalosporin should be cautiously considered.

Keywords: AmpC β-lactamase; Bacteremia; Enterobacter; Tazobactam piperacillin; Third-generation cephalosporin.